Chemoradiotherapy for Head and Neck Cancer
Author Information
Author(s): Kim J G, Sohn S K, Kim D H, Baek J H, Jeon S B, Chae Y S, Lee K B, Park J S, Sohn J H, Kim J C, Park I K
Primary Institution: Kyungpook National University Hospital
Hypothesis
The study aimed to evaluate the efficacy and safety of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
Conclusion
Concurrent chemoradiotherapy with capecitabine and cisplatin was found to be well tolerated and effective in patients with locally advanced SCCHN.
Supporting Evidence
- 29 complete responses (78.4%) and 6 partial responses (16.2%) were confirmed after treatment.
- The estimated overall survival rate at 2 years was 76.8%.
- Grade 3 or 4 neutropenia occurred in only two patients.
Takeaway
Doctors tested a new treatment for a type of throat cancer using two medicines together, and it worked well for most patients.
Methodology
The study involved 37 patients receiving two cycles of chemotherapy with capecitabine and cisplatin, followed by radiotherapy.
Limitations
The follow-up period was relatively short to compare the survival rate directly.
Participant Demographics
Median age was 61 years, with 83.8% male and 59.5% having stage III disease.
Statistical Information
Confidence Interval
95% CI; 87.0–102.2%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website